Icagen, Inc. · Durham, NC United States ·(NASDAQ (GM): ICGN)
Company Description
View Icagen, Inc. Locations On A US Map
This link will open in a new window
This link will open in a new window Icagen wants to set the market for ion channel modulators on fire. The development-stage biotech focuses on treatments for epilepsy, asthma, pain, and inflammation by regulating the inflow into cells of such ions as calcium, potassium, and sodium. Icagen's lead candidate, senicapoc for sickle cell disease, died in 2007 following lackluster Phase III clinical trial results. The drug was being developed in a partnership with
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Key Icagen, Inc. Financials
| Company Type | Public - NASDAQ (GM): ICGN Single Location |
| Fiscal Year-End | December |
| 2008 Sales (mil.) | $12.3 |
| 2008 Employees | 73 |
Icagen, Inc. Executives
15 executives listed for Icagen, Inc.'s Durham, NC location.
| Title | Name & Bio | Contact |
| Chairman | Charles Sanders | Network |
| President, CEO, and Director | P. Kay Wagoner | Network |
| EVP Finance and Corporate Development, CFO, and Treasurer | Richard Katz | Network |
Competition
Competitive Landscape for Icagen, Inc.
Demand often depends on the income of consumers or the profitability of business customers, because many technology products and services are expensive. The profitability of individual companies is driven by their ability to develop and market new products. Large companies often have advantages in access to capital and marketing. Small companies can compete successfully if they have expertise in a particular field of knowledge. The industry is capital-intensive: average annual revenue per worker is nearly $300,000. To read the full description, subscribe now.Top Icagen, Inc. Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!